bioAffinity Technologies (NASDAQ:BIAF) Upgraded by Wall Street Zen to “Hold” Rating

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings cut shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

bioAffinity Technologies Stock Down 1.2%

BIAF stock opened at $0.83 on Friday. bioAffinity Technologies has a fifty-two week low of $0.69 and a fifty-two week high of $13.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The stock has a market capitalization of $3.93 million, a price-to-earnings ratio of -0.07 and a beta of -1.33. The business’s fifty day moving average price is $1.75 and its two-hundred day moving average price is $1.77.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%. The company had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $1.48 million.

Institutional Trading of bioAffinity Technologies

Institutional investors have recently modified their holdings of the stock. Sabby Management LLC acquired a new stake in shares of bioAffinity Technologies during the 3rd quarter worth $719,000. J. Safra Sarasin Holding AG acquired a new position in bioAffinity Technologies in the first quarter valued at about $164,000. Geode Capital Management LLC acquired a new position in bioAffinity Technologies in the fourth quarter valued at about $36,000. Finally, Scientech Research LLC bought a new stake in bioAffinity Technologies during the third quarter worth about $49,000. 1.64% of the stock is currently owned by institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.